2008
DOI: 10.1016/j.amjcard.2008.06.018
|View full text |Cite
|
Sign up to set email alerts
|

Relation of Atrial Fibrillation to Glomerular Filtration Rate

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
69
0
14

Year Published

2010
2010
2018
2018

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 111 publications
(89 citation statements)
references
References 16 publications
6
69
0
14
Order By: Relevance
“…5 A recent study performed in Japan further demonstrated that the prevalence of AF gradually increased with a decreasing GFR, which was unrelated to the age increases. 4 The findings of these previous studies suggest that processes influencing the development of AF likely occur early in the course of the decline in the GFR.…”
Section: Renal Function Atrial Substrate Properties and Afmentioning
confidence: 91%
“…5 A recent study performed in Japan further demonstrated that the prevalence of AF gradually increased with a decreasing GFR, which was unrelated to the age increases. 4 The findings of these previous studies suggest that processes influencing the development of AF likely occur early in the course of the decline in the GFR.…”
Section: Renal Function Atrial Substrate Properties and Afmentioning
confidence: 91%
“…Several clinical and population-based studies have shown that the prevalence of AF is independently associated with decreased eGFR and increased levels of urinary albumin (11)(12)(13). A recent study reported that decreased eGFR is associated with an increased risk of subsequent new onset AF in a large scale of community-based cohort (14).…”
Section: Discussionmentioning
confidence: 99%
“…128 However, patients with stage 4 to 5 CKD are known to be at increased risk for atrial fibrillation owing to structural and electric atrial remodeling. 131,132 In the Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF), Ͼ14 000 patients with atrial fibrillation were randomized to 20 mg rivaroxaban once daily (or 15 mg in patients with moderate renal impairment at screening) or to dose-adjusted warfarin (titrated to an international normalized ratio of 2.5). Rivaroxaban was found to be noninferior to warfarin in terms of the combined primary end point of stroke and systemic embolisms and was superior to warfarin in the on-treatment but not in the stricter intention-to-treat analysis, raising concerns about potentially poor adherence with rivaroxaban in real-world practice.…”
Section: Impact Of Antithrombotic Therapies In Ckd Patients With Atrimentioning
confidence: 99%